QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.104.070656v1 311/2/576    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Iyengar, S. Articles by Simmons, R. M. A. Search for Related Content PubMed PubMed Citation Articles by Iyengar, S. Articles by Simmons, R. M. A.

NEUROPHARMACOLOGY

Efficacy of Duloxetine, a Potent and Balanced Serotonin-Norepinephrine Reuptake Inhibitor in Persistent Pain Models in Rats

Lilly Research Laboratories, Eli Lilly & Co., Lilly Corporate Center, Indianapolis, Indiana

5-Hydroxytryptamine (serotonin) (5-HT) and norepinephrine (NE) are implicated in modulating descending inhibitory pain pathways in the central nervous system. Duloxetine is a selective and potent dual 5-HT and NE reuptake inhibitor (SNRI). The ability of duloxetine to antagonize 5-HT depletion in para-chloramphetamine-treated rats was comparable with that of paroxetine, a selective serotonin reuptake inhibitor (SSRI), whereas its ability to antagonize NE depletion in -methyl-m-tyrosine-treated rats was similar to norepinephrine reuptake inhibitors (NRIs), thionisoxetine or desipramine. In this paradigm, duloxetine was also more potent than other SNRIs, including venlafaxine or milnacipran and amitriptyline. Low doses of the SSRI paroxetine or the NRI thionisoxetine alone did not have an effect on late phase paw-licking pain behavior in the formalin model of persistent pain; however, when combined, significantly attenuated this pain behavior. Duloxetine (3–15 mg/kg intraperitoneal) significantly attenuated late phase paw-licking behavior in a dose-dependent manner in the formalin model and was more potent than venlafaxine, milnacipran, and amitriptyline. These effects of duloxetine were evident at doses that did not cause neurologic deficits in the rotorod test. Duloxetine (5–30 mg/kg oral) was also more potent and efficacious than venlafaxine and milnacipran in reversing mechanical allodynia behavior in the L5/L6 spinal nerve ligation model of neuropathic pain. Duloxetine (3–30 mg/kg oral) was minimally efficacious in the tail-flick model of acute nociceptive pain. These data suggest that inhibition of both 5-HT and NE uptake may account for attenuation of persistent pain mechanisms. Thus, duloxetine may have utility in treatment of human persistent and neuropathic pain states.

Address correspondence to: Dr. Smriti Iyengar, Eli Lilly & Co., Lilly Corporate Center, Indianapolis, IN 46285. E-mail: iyengar{at}lilly.com

This article has been cited by other articles:

				P. A. Krieter, M. Gohdes, T. J. Musick, F. P. Duncanson, and W. E. Bridson Pharmacokinetics, Disposition, and Metabolism of Bicifadine in Humans Drug Metab. Dispos., February 1, 2008; 36(2): 252 - 259. [Abstract] [Full Text] [PDF]

				A. S. Basile, A. Janowsky, K. Golembiowska, M. Kowalska, E. Tam, M. Benveniste, P. Popik, A. Nikiforuk, M. Krawczyk, G. Nowak, et al. Characterization of the Antinociceptive Actions of Bicifadine in Models of Acute, Persistent, and Chronic Pain J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 1208 - 1225. [Abstract] [Full Text] [PDF]

				Z.-Q. Zhao, S. Chiechio, Y.-G. Sun, K.-H. Zhang, C.-S. Zhao, M. Scott, R. L. Johnson, E. S. Deneris, K. J. Renner, R. W. Gereau IV, et al. Mice Lacking Central Serotonergic Neurons Show Enhanced Inflammatory Pain and an Impaired Analgesic Response to Antidepressant Drugs J. Neurosci., May 30, 2007; 27(22): 6045 - 6053. [Abstract] [Full Text] [PDF]

				L. Leventhal, V. Smith, G. Hornby, T. H. Andree, M. R. Brandt, and K. E. Rogers Differential and Synergistic Effects of Selective Norepinephrine and Serotonin Reuptake Inhibitors in Rodent Models of Pain J. Pharmacol. Exp. Ther., March 1, 2007; 320(3): 1178 - 1185. [Abstract] [Full Text] [PDF]

				D. C. Deecher, C. E. Beyer, G. Johnston, J. Bray, S. Shah, M. Abou-Gharbia, and T. H. Andree Desvenlafaxine Succinate: A New Serotonin and Norepinephrine Reuptake Inhibitor J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 657 - 665. [Abstract] [Full Text] [PDF]

				J. C. Nelson, M. M. Wohlreich, C. H. Mallinckrodt, M. J. Detke, J. G. Watkin, and J. S. Kennedy Duloxetine for the Treatment of Major Depressive Disorder in Older Patients Am J Geriatr Psychiatry, March 1, 2005; 13(3): 227 - 235. [Abstract] [Full Text] [PDF]

				C. K. Jones, S. C. Peters, and H. E. Shannon Efficacy of Duloxetine, a Potent and Balanced Serotonergic and Noradrenergic Reuptake Inhibitor, in Inflammatory and Acute Pain Models in Rodents J. Pharmacol. Exp. Ther., February 1, 2005; 312(2): 726 - 732. [Abstract] [Full Text] [PDF]